Beatriz Olalla-Sastre

Ms. Beatriz Olalla-Sastre

FJD
+3
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PPPilar Puig-Serra
Pilar Puig-Serra
MCMaria Cruz Casado-Rosas
Maria Cruz Casado-Rosas
MMMarta Martinez-Lage
Marta Martinez-Lage
Beatriz Olalla-SastreBeatriz Olalla-Sastre
Beatriz Olalla-Sastre
AAAlejandro Alonso-Yanez
Alejandro Alonso-Yanez
SRSandra Rodriguez-Perales
Sandra Rodriguez-Perales
CRISPR/Cas is a prokaryotic self-defense system, widely known for its use as a gene-editing tool. Because of their high specificity to detect DNA and RNA sequences, different CRISPR systems have been adapted for nucleic acid detection. CRISPR detection technologies differ highly among them, since they are based on four of the six major subtypes of CRISPR systems. In just 5 years, the CRISPR diagnostic field has rapidly expanded, growing from a set of specific molecular biology discoveries to multiple FDA-authorized COVID-19 tests and the establishment of several companies. CRISPR-based detection methods are coupled with pre-existing preamplification and readout technologies, achieving sensitivity and reproducibility comparable to the current gold standard nucleic acid detection methods. Moreover, they are very versatile, can be easily implemented to detect emerging pathogens and new clinically relevant mutations, and offer multiplexing capability. The advantages of the CRISPR-based diagnostic approaches are a short sample-to-answer time and no requirement of laboratory settings; they are also much more affordable than current nucleic acid detection procedures. In this review, we summarize the applications and development trends of the CRISPR/Cas13 system in the identification of particular pathogens and mutations and discuss the challenges and future prospects of CRISPR-based diagnostic platforms in biomedicine.

12 June 2024 in Cytotherapy
Verified
Journal Article
Closed access
Beatriz Olalla-SastreBeatriz Olalla-Sastre
Beatriz Olalla-Sastre
PRPaula Rio
Paula Rio